Prostate-specific antigen monitoring for men with pathogenic BRCA2 variants, testicular ultrasound and tumor marker evaluation for men at high risk of testicular cancer, and hematological evaluations for those with severe spermatogenic failure and inexplicable systemic symptoms are a few examples [129]. This evidence concerns the gene KLK3 and neoplasm.